1. Home
  2. SLNO vs PECO Comparison

SLNO vs PECO Comparison

Compare SLNO & PECO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLNO
  • PECO
  • Stock Information
  • Founded
  • SLNO 1999
  • PECO 1991
  • Country
  • SLNO United States
  • PECO United States
  • Employees
  • SLNO N/A
  • PECO N/A
  • Industry
  • SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • PECO Real Estate Investment Trusts
  • Sector
  • SLNO Health Care
  • PECO Real Estate
  • Exchange
  • SLNO Nasdaq
  • PECO Nasdaq
  • Market Cap
  • SLNO 3.8B
  • PECO 4.2B
  • IPO Year
  • SLNO 2014
  • PECO 2021
  • Fundamental
  • Price
  • SLNO $65.46
  • PECO $34.53
  • Analyst Decision
  • SLNO Strong Buy
  • PECO Buy
  • Analyst Count
  • SLNO 9
  • PECO 7
  • Target Price
  • SLNO $116.78
  • PECO $38.00
  • AVG Volume (30 Days)
  • SLNO 1.7M
  • PECO 927.0K
  • Earning Date
  • SLNO 11-05-2025
  • PECO 10-23-2025
  • Dividend Yield
  • SLNO N/A
  • PECO 3.77%
  • EPS Growth
  • SLNO N/A
  • PECO 13.92
  • EPS
  • SLNO N/A
  • PECO 0.55
  • Revenue
  • SLNO $32,656,999.00
  • PECO $694,639,000.00
  • Revenue This Year
  • SLNO N/A
  • PECO $9.97
  • Revenue Next Year
  • SLNO $182.29
  • PECO $5.40
  • P/E Ratio
  • SLNO N/A
  • PECO $62.50
  • Revenue Growth
  • SLNO N/A
  • PECO 10.31
  • 52 Week Low
  • SLNO $41.50
  • PECO $32.40
  • 52 Week High
  • SLNO $90.32
  • PECO $40.12
  • Technical
  • Relative Strength Index (RSI)
  • SLNO 51.66
  • PECO 55.63
  • Support Level
  • SLNO $63.02
  • PECO $32.98
  • Resistance Level
  • SLNO $72.88
  • PECO $34.08
  • Average True Range (ATR)
  • SLNO 4.25
  • PECO 0.49
  • MACD
  • SLNO 1.03
  • PECO 0.08
  • Stochastic Oscillator
  • SLNO 56.61
  • PECO 99.04

About SLNO Soleno Therapeutics Inc.

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

About PECO Phillips Edison & Company Inc.

Phillips Edison & Co Inc is a real estate investment trust. The company also operates a third-party investment management business providing property management and advisory services to four unconsolidated institutional joint ventures, in which it has a partial ownership interests, and one private fund. It invests in well-occupied, grocery-anchored neighborhood and community shopping centers. It holds an integrated in-house operating platform built on market of expertise designed to optimize property value and consistently deliver a great shopping experience.

Share on Social Networks: